AGEN highlights progress on botensilimab and balstilimab combo, targeting immunotherapy-resistant cancers amid financial improvements.
Agenus (NASDAQ:AGEN) outlined its focus on advancing botensilimab and balstilimab (BOT/BAL), an immunotherapy combination for historically resistant cancers, including MSS colorectal cancer. The company aims to expand clinical evidence and pursue regulatory pathways in the U.S. and Europe.
CEO Garo Armen described the past year as pivotal, marked by strategic decisions to prioritize BOT/BAL. The regimen, combining an Fc-engineered CTLA-4 antibody and a PD-1 antibody, is positioned as distinct from other doublets, with trials showing potential in broader immune activation.
Agenus also emphasized strengthening its balance sheet and operational foundation to support phase 3 development and patient access initiatives.